Trial Profile
A global, randomized, pivotal Phase III clinical trial of tislelizumab for the treatment of gastric cancer and oesophageal cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 21 Nov 2018
Price :
$35
*
At a glance
- Drugs Tislelizumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 21 Nov 2018 New trial record
- 07 Nov 2018 According to a Beigene media release, the company plans to initiate this trial in 2018 or early 2019.